Complete Response to Combination Nivolumab and Ipilimumab in Recurrent Neuroendocrine Carcinoma of the Cervix

Thomas A. Paterniti, Katie Dorr, Asad Ullah, Joseph White, Hadyn Williams, Sharad Ghamande

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Small cell neuroendocrine carcinoma of the cervix is a rare, aggressive tumor treated with a combination of surgery, chemotherapy, and radiation. Survival rates are poor, and innovative therapies are needed. CASE: A 52-year-old woman was diagnosed with small cell neuroendocrine carcinoma of the cervix. Over a 10-year period, she was treated with six different systemic therapeutic regimens, underwent planned hysterectomy with bilateral salpingo-oophorectomy, and received radiation to the pelvis and brain. After a second recurrence of disease, she was treated with a combination of nivolumab and ipilimumab and experienced a complete and durable response. CONCLUSION: The combination of nivolumab and ipilimumab may represent a promising new treatment option for recurrent small cell neuroendocrine carcinoma of the cervix.

Original languageEnglish (US)
Pages (from-to)813-816
Number of pages4
JournalObstetrics and gynecology
Volume138
Issue number5
DOIs
StatePublished - Nov 1 2021

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'Complete Response to Combination Nivolumab and Ipilimumab in Recurrent Neuroendocrine Carcinoma of the Cervix'. Together they form a unique fingerprint.

Cite this